Drug information of Piribedil

Piribedil


Treatment of Parkinson disease, either as monotherapy without levodopa or in combination with levodopa therapy

Mechanism of effect

Piribedil is a piperazine derivative, a non-ergot dopamine receptor agonist, whose pharmacology is unusual, in that it is an agonist at D2 and D3 receptors and an α2-adrenoceptor agonist.

Pharmacodynamic

he pharmacology of piribedil, a new dopamine agonist, is reviewed, justifying the rationale of its use as an antiparkinsonian agent. Piribedil is a synthetic chemical compound which does not possess an ergot structural profile. This drug and its main active metabolites show a high affinity for the dopaminergic receptor subtypes: D2 (Ki = 1.3 10-7 mol/L), D3 (Ki = 2.4 10-7 mol/L) and probably D1

Pharmacokinetics

They are characterised by rapid absorption after oral intake, large volume of distribution and low clearance relative to hepatic blood flow, with extensive metabolism. The mechanism of action of amantadine remains elusive. It is well absorbed and widely distributed. Since elimination is primarily by renal clearance

Drug indications

parkinson , Bipolar disorder , vertigo

Dosage

Parkinson disease: Oral: Note: Dosage should be introduced gradually, may increase by 50 mg every 3 days

Patients NOT on levodopa therapy: 150 mg to 250 mg daily in 3 to 5 divided doses

Combination with levodopa therapy: Reduced dosages may be given as a supplement to levodopa therapy (ie, 20 mg piribedil per 100 mg levodopa; 80 mg to 140 mg daily). Note: Use of 20 mg tablets is more suitable for this indication; however, availability of 20 mg tablets may vary per country/region.

Drug contraindications

pregnancy , syncope , Hypersensitivity


Ask a Pharmacist


User's questions
    No comments yet.